Don’t Blink at the DraftKings Dump. The SpaceX Sale Is Cathie Wood’s Loudest Signal
(SeaPRwire) – By: Oliver Hawthorne
The October 9 trade sheet from ARK Invest reads like a portfolio-wide confession. Cathie Wood sold DraftKings, CareDx, SpaceX, AMD, Alphabet, Robinhood, Shopify, the Bitcoin ETF, and Iridium Communications in a single session. That is not a tidy tax-loss harvest. It is a deliberate cliff dive out of consumer tech, mega-cap compute, and speculative mobile trading. The action on the buy side is even louder. Almost every fresh dollar went into ARKG, the genomics fund, which added CRISPR Therapeutics, Intellia, Beam, Nurix, Guardant Health, Kymera, Compass Pathways, Almar Biosciences, and Freenome. The market rewarded that call immediately. ARKG closed up more than 4 percent on Friday. CRISPR jumped 5.85 percent. Beam rose 4.47 percent. Compass Pathways climbed 4.62 percent. DraftKings, by contrast, fell 1.46 percent. AMD dropped 2.03 percent. The crowd, though, is not on board. Retail sentiment on Stocktwits around ARKG is bearish right now. That gap between institutional behavior and the public mood is one of the cleanest contrarian setups of this cycle.
The scale of the sell-down matters. ARK sold 397,016 DraftKings shares through the ARKW and ARKF funds, worth roughly $7.89 million. That continues a multi-day sell-off in DKNG. At the same time, ARKG cut 57,911 CareDx shares, valued at $3.60 million, and kept trimming that position all week. The ARK Innovation ETF reduced stakes in five high-profile names: SpaceX, Advanced Micro Devices, Alphabet, Robinhood Markets, and Shopify. ARKG also cut Personalis. The ARK Space & Defense ETF dumped Iridium Communications. None of those are weak balance sheets. SpaceX is a hard-to-access private asset. AMD has real data-center traction. Alphabet prints cash. Selling private SpaceX shares is the brutal part of this disclosure. You do not casually liquidate a pre-IPO stock with long-term structural demand unless you need firepower for something with more perceived upside. That something is a broad basket of gene-editing and molecular diagnostic companies. ARK bought 21,487 shares of CRISPR Therapeutics for $1.08 million. It added 48,171 shares of Intellia Therapeutics for $606,954. It grabbed 56,096 shares of Nurix Therapeutics, valued at $1.24 million. Guardant Health received a $1.19 million order. Kymera, Compass Pathways, Almar, and Freenome also saw inflows. The pattern is impossible to miss. This is a frontier rotation, a sprint toward early-stage genomics, and a retreat from crowded tech names that have already enjoyed their valuation expansion.
The real logic here is not about daily performance. Unprofitable drug developers need cash to run clinical programs. ARK, by buying them now, is positioning itself ahead of a wave of secondary offerings. When a company like Intellia or Beam announces a raise, the share price usually takes a hit. ARK can buy more because assets under management keep flowing as the fund outperforms. That is the loop. It only breaks if clinical readouts fail. Then the dilution becomes toxic. But the bearish Stocktwits sentiment means the general public is not yet chasing this rally. That gives ARK room to fill its basket at prices that still look cheap compared to a 2027 scenario where multiple late-stage trials can produce visible commercial revenue. The real risk is not regulatory scrutiny or U.S. Food and Drug Administration indifference. It is neglect over time. If the catalysts come and go without actual product sales, ARKG turns into a giant machine that feeds capital into an endless pipeline of hope. If the catalysts land with strong safety and efficacy data, these gene-editing names become takeover targets for big pharmaceutical companies. There is no middle ground here. Private SpaceX shares were sold to fund a binary bet. That single move frames the entire trade: high conviction, high burn, high reward. The winner will be known only when the data arrives. Until then, the only disciplined trade is to respect the allocation change and ignore the crowd’s mood. Execution, not sentiment, is the whole game.
Author bio: Oliver Hawthorne, Principal Correspondent for The Global Tech Review, covers technology valuations, speculative capital flows, and genomics disruption. He has spent more than two decades reporting on how frontier science changes investment logic across global markets.